12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Biocon, Bristol-Myers deal

Biocon granted Bristol-Myers an exclusive option to license worldwide rights outside of India to diabetes product IN-105. Biocon will further characterize the oral insulin analog through Phase II testing, after which BMS would be responsible for further development and commercialization outside of India....

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >